Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(16 sites)
Albania
University Center Mother Theresa , Hospital - Onco-hematology department, Tirana Armenia
Yeolyan Hematology. , and Oncology Center -, Yerevan Belgium
CHU Saint-Pierre Clinical Trials Unit, Brussels Universitair Ziekenhuis Brussel (UZBrussel) - Department of Anesthesiology and Perioperative Medicine, Brussels University Hospitals Leuven Pediatrisch hemato-oncology, Leuven Bosnia and Herzegovina
University Clinical Hospital , Mostar, Mostar France
Hôpital Béclère Service de Pédiatrie Centre de Référence des Maladies Héréditaires du Métabolisme Hépatique (CRMHMH), Clamart Hôpital Jeanne de Flandre Antenne du CIC pédiatrique - Niveau 0 CHU de Lille, Lille Hôpital Armand Trousseau Service Hématologie et Oncologie Pédiatrique, Paris Italy
Instituto Nazionale dei Tumori, Milan Citta della Salute e della Scienza di Torino, Torino Maternal and Child Health Institute IRCCS Burlo Garofolo, Pain and pediatric palliative care service, Trieste Japan
National Center for Child Health and Development, Tokyo North Macedonia
PHI University Clinic for Children's , Surgery, Skopje University Clinic for Childrens Diseases , Department of Oncology, Hematology and , Malignant Hemopathy, Skopje